Preliminary report of domperidone (R 33182), a new antiemetic compound. A pilot study.
The effect of domperidone (R 33 812), a new antiemetic, was studied in 27 patients presenting with postoperative vomiting and staying for at least six hours in a recovery room. All patients received 4 mg domperidone intravenously because of the vomiting. Nineteen patients were fully protected during the subsequent 6 hours observation period, 8 patients required a second 4 mg-dose: only one of these 8 patients was not protected at all. No side-effects were observed.
D000328:Adult; D000368:Aged; D000758:Anesthesia / Q000009:adverse effects*; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control*; D014839:Vomiting / Q000517:prevention & control*
D000932:Antiemetics; D001562:Benzimidazoles; D010880:Piperidines